Member Info for Blessed22

I d be happy with 5% given how today turned out to be.
Ticking up at 174 would push it higher. Just need some buying pressure.
Finger crossed

Bulls vs bears on the 5min chart just above the 200ma.
If it holds 50ma to cross 200ma soon and SP could tick up higher.

That's what I was expecting.
It's going the other way though!

Little tree shake.

Bounce?

Bottom of the rising channel was 161
We touched it and we bounced.
Technicals are good as long as above 20MA.
Upper end of channel 220.
A 7/10% upside tomorrow would make sense.

Therapeutics will always be in need for the foreseeable future no matter what.
Vaccines are not the way out of this although necessary.
Poorer countries probably won't get a single dose this year and early treatments needed urgently.

EUA before end of February.

AstraZeneca's main trial in Britain started testing on adults no older than 55 because it initially focused on healthcare personnel and frontline workers in active duty.

"Researchers at Oxford University said in a paper published in medical journal The Lancet on Dec. 8, when details of key vaccine trials held in Britain and Brazil were released, that efficacy data based on infections in the elderly were still limited"

Limited data.
Timely approved in the UK in a blink of an eye beacuse suited the the government agenda.

195 opening?? :)

"It will enable progressing approval for SNG001 as a treatment for COVID-19".

Base of the uptrend channel is the 20MA.
Rising channel poniting at 200+ in the near term.
50MA in the run up to cross the 200MA.

Any news realease and you ll have to pay a considerable higher price than now to be on board.

ATB

Just remind yourself that we have a drug that could be used for the fight against the pandemic and for the future generations applicable for any respiratory and influenza-like viruses.

The potential is is unquantifiable!

All your post have been deleted.

Scammer

I believe Fauci's last video confirms that thing are moving in a certain direction: ANTIVIRALS.

USA RNS and inclusion in the ACTIV2 imo will be released this coming week.

Looking at other companies you can see that some MaBs already have EUA but there is not a big uptake given that the drugs need to be infused and those data are limited to long term care facilities and present a distribution barrier. Besides, other MaBs studies on the new variants will require further studies throughout the year.
Despite some govs order they won't be the silver bullet.

Re Antivirals we need more positive data in order to get EUA and preliminary reviews of the ongoing P3 trial can come in our favour given Fauci's confirmed agenda.
He's saying that this can be the game changer and explicitly mention "7/10 days course treatment".

Demand for SNG001 will be high both in the US and other countries. ACTIV2 would be of enormous value.

"CTAP plays an important role in these efforts by providing FDA subject matter expertise for ACTIV initiatives, including for clinical trial design and conduct and relevant FDA regulatory standards for therapeutics.  Under the CTAP program, FDA can better ensure that critical focus is placed on reviewing those therapies prioritized by the ACTIV partnership.  The involvement of FDA in the ACTIV partnership will also help ensure these reviews are more efficient, particularly in evaluating proposed pre-clinical and clinical studies that received ACTIV input"

There are hurdles to jump but the ride is becoming more interesting.

Fauci focusing again on antiviral drugs.

" The real goal is to get a direct powerful antiviral drug to patients as soon as they come in".

He mentions that giving them a 7/10 days treatment would prevent them to progress to severe disease.

Interesting

A trial of 89 patients which still needs further large scale clinical studied.

End.

That's your thought Scinv but accept that many people disagree with you here. You are showing no tolerance.

People have different opinions and must be respected.
If you believe what you believe just move somewhere else there are plenty of opportunities to make decent money these days.

But you need to learn that you cannot force people to see things the way you do. Those are only your thoughts not proven facts. So there is always a degree of uncertainty in what you saying and the 21£ per treatment is bullsh*t.

Keep it balanced and dont post hundreds time in an hour beacuse it can only go against you.

Incomprehensible how someone who has invested in the company can spout garbage on his own investment.
Delusional thoughts that's what they are.

We won't be the only treatment but if successful the we ll have high rewards.

All these "i know it all" type of persons have either lost all their money investing and feel resentful or their low IQ stopped them from succeding in life or at least stopped from learning how to social interact with others( even on an anonymous board).

Whatever it is I prefer to ignore ( filter the non sense) but hope that in a way life will teach them some lesson which clearly haven't yet been learnt.

Another critical initiative is the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership, coordinated by the Foundation for the National Institutes of Health (FNIH).  ACTIV involves a collaboration among government and industry partners, including FDA, to prioritize vaccine and therapeutic candidates, streamline clinical trials, and rapidly expand the clinical research resources focused on developing therapies for the COVID-19 pandemic.  Among other things, ACTIV government and industry partners provide subject matter expertise and/or funding to identify, prioritize and facilitate the entry of some of the most promising candidates into clinical trials.

CTAP plays an important role in these efforts by providing FDA subject matter expertise for ACTIV initiatives, including for clinical trial design and conduct and relevant FDA regulatory standards for therapeutics.  Under the CTAP program, FDA can better ensure that critical focus is placed on reviewing those therapies prioritized by the ACTIV partnership.  The involvement of FDA in the ACTIV partnership will also help ensure these reviews are more efficient, particularly in evaluating proposed pre-clinical and clinical studies that received ACTIV input.

https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap#activ

Being part of the ACTIV would be of enormous value.

Have a good weekend all

Nothing new but a good recap.

https://www.google.com/amp/s/www.proactiveinvestors.co.uk/companies/amp/news/219796

It is funny that they have only mentioned antivirals today straight after Biden's first day and his executive orders saying that the US is launching a major antiviral programme.

Vallance you are a funny man!